Skip to main content

Exploring JAK Inhibitors for Inflammatory Skin Disorders: Improving Outcomes for Atopic Dermatitis

Program Overview
Atopic dermatitis (AD) is an increasingly prevalent chronic systemic inflammatory disease, with significant and often underappreciated impacts on quality of life. Patients with more severe forms of AD tend to not respond to first-line therapies and traditional systemic second-line treatments can cause significant adverse effects that preclude their long-term use. An improved understanding of disease etiology has led to the development of new therapies that target pathological pathways involved in AD, including the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway. This webinar will review the clinical manifestations and assessment of AD and provide a practical approach to AD treatment with the newer targeted agents, particularly in individuals with more severe AD, for whom other systemic and non-targeted therapies are not effective. This program has been developed for US dermatology allied healthcare professionals (HCPs) and will include several interactive case study discussions.

Target Audience
This initiative is intended for US dermatology allied HCPs, including physician assistants, nurse practitioners, and nurses, as well as other allied HCPs who may be involved in the management of patients with AD.

Educational Objectives
Upon completion of this activity, the learner should be able to:

  • Describe the burden of AD, including clinical manifestations, associated disorders, and psychosocial impact
  • Describe the epidemiology of AD and disease risk factors
  • Describe the role of specific immunological pathways, such as JAK/STAT, in the pathogenesis of AD
  • Differentiate the mechanisms of action of emerging systemic therapies for AD, including JAK inhibitors
  • Evaluate the benefits and risks of JAK inhibitors and other emerging therapy classes in AD
  • Discuss clinical considerations associated with the potential implementation of emerging AD therapies into practice

  • Introduction
  • Burden of AD: Not Just Superficial
  • Targeting the Pathophysiology of AD
  • Benefits/Risks of Emerging Systemic Therapies for AD
  • Q&A

Brett King, MD, PhD
Associate Professor of Dermatology
Yale University School of Medicine
New Haven, CT

Sharna Givans, DNP, APRN, FNP-BC
Tampa, FL

Douglas DiRuggiero, DMSc, PA-C
Skin Cancer and Cosmetic Dermatology Center
Rome, GA

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Criteria for Success
Certificates of completion will be awarded based on the participant’s attendance and submission of the activity evaluation/claim credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

1.5 ANCC contact hours.

Nurse Practitioners
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.This activity is approved for 1.5 contact hour(s) (which includes 0.5 hour(s) of pharmacology).

Provider Information
This program is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.

Commercial Support:
This activity is supported by an educational grant from Pfizer, Inc.

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

AKH Privacy Policy (link: